

Contents

Preface — VII

List of contributing authors — XVII

Manmeet Kaur, Mandeep Kaur, Tania Bandopadhyay, Aditi Sharma, Anu Priya,
Arvind Singh and Bubun Banerjee

1	Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs — 1
1.1	Introduction — 1
1.2	Naturally occurring heterocyclic anti-cancer drugs — 2
1.2.1	Actinomycin D — 2
1.2.2	Arglabin — 2
1.2.3	Bleomycin — 3
1.2.4	Carzinophilin — 3
1.2.5	Daunorubicin — 4
1.2.6	Doxorubicin — 4
1.2.7	Epirubicin — 5
1.2.8	Idarubicin — 5
1.2.9	Mithramycin — 6
1.2.10	Mitomycin C — 6
1.2.11	Neocarzinostatin — 7
1.2.12	Paclitaxel and docetaxel — 7
1.2.13	Pentostatin — 8
1.2.14	Peplomycin — 8
1.2.15	Trabectedin — 9
1.2.16	Vinflunine — 9
1.2.17	Zinostatin — 10
1.2.18	Cryptophycin F — 10
1.2.19	Homoharringtonine — 11
1.3	Natural product inspired heterocyclic anti-cancer drugs — 11
1.3.1	Belotecan — 11
1.3.2	Cabazitaxel — 12
1.3.3	Etoposide — 13
1.3.4	Irinotecan — 13
1.3.5	Ixabepilone — 13
1.3.6	Teniposide — 14
1.3.7	Topotecan — 15
1.3.8	Valrubicin — 16
1.3.9	Vinorelbine — 17
1.4	Synthetic heterocyclic anti-cancer drugs — 17

1.5	Conclusions — 41
	References — 42

Shashi Kiran Misra and Kamla Pathak

2	Naturally occurring heterocyclic anticancer compounds — 55
2.1	Introduction — 55
2.2	N-based natural occurring heterocyclic molecules — 56
2.2.1	Vinka alkaloids (vincristine and vinblastine) — 56
2.2.2	Cruciferous vegetables — 57
2.2.3	Marine sources (meridianins, dragmacidins and makaluvamines) — 58
2.2.4	Lamellarins and trabectedin — 58
2.2.5	Piperine, sanguinoline, tetrandrine — 60
2.2.6	Evodiamine, camptothecin, berberin — 62
2.2.7	Other natural heterocyclic anticancerous compounds — 63
2.3	Oxygen based natural occurring heterocyclic molecules — 64
2.3.1	Paclitaxel — 65
2.3.2	Halichondrin B — 65
2.3.3	Quercetin, myricetin and kaempferol — 66
2.3.4	Chalcones — 69
2.3.5	Heterocyclic antibiotics (doxorubicin, bleomycin and dactinomycin) — 69
2.4	Sulphur based natural occurring heterocyclic compounds — 72
2.4.1	Brugine — 72
2.4.2	Fucoidan — 72
2.4.3	Carrageenan — 73
2.4.4	Phytoalexins and phenethyl isothiocyanate — 75
2.5	Conclusions — 76
	References — 76

Arvind Singh, Amartya Basu, Aditi Sharma, Anu Priya, Manmmeet Kaur, Gurpreet Kaur and Bubun Banerjee

3	Lawson (2-hydroxy-1,4-naphthaquinone) derived anticancer agents — 83
3.1	Introduction — 83
3.2	Synthesis of lawson derived synthetic organic scaffolds having anti-cancer activities — 85
3.2.1	Synthesis of 6-aryl-benzo[<i>h</i>][1,2,4]-triazolo[5,1- <i>b</i>]quinazoline-7,8-diones — 85
3.2.2	Synthesis of 13-aryl-13 <i>H</i> -benzo[<i>g</i>]benzothiazolo[2,3- <i>b</i>]quinazoline-5,14-diones — 87
3.2.3	Synthesis of benzo[<i>g</i>]chromenes — 87
3.2.4	Synthesis of 7,7- <i>a</i> -dihydro-5 <i>H</i> -benzo[<i>g</i>]benzofuro[3,2- <i>c</i>]chromene-5,13(12 <i>aH</i>)-dione derivatives — 87

3.2.5	Synthesis of pyrano- and furanonaphthoquinones —	89
3.2.6	Synthesis of 14-aryl-12 <i>H</i> -dibenzo[<i>a,h</i>]xanthene-12,13(14 <i>H</i>)-diones —	91
3.2.7	Synthesis of 1-((aryl)(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl)-4-phenyl-1,2,4-triazolidine-3,5-dione derivatives —	92
3.2.8	Synthesis of 2-benzylawsone —	93
3.2.9	Synthesis of bislawsone derivatives —	94
3.2.10	Synthesis of 3-(aminomethyl)naphthoquinones —	94
3.2.11	Synthesis of (2 <i>E</i> ,4 <i>E</i>)-1,4-dioxo-1,4-dihydronaphthalen-2-yl-5(benzo[<i>d</i>][1,3]dioxol-5-yl)penta-2,4-dienoate —	95
3.2.12	Synthesis of benzo[<i>c</i>]acridine-5,6(7 <i>H</i> ,12 <i>H</i>)-dione derivative —	96
3.2.13	Synthesis of 2-ethyl-7-(4-methylpentyl)naphtho[1,2- <i>b</i>]furan-4,5-dione —	96
3.3	Synthesis of lawsone derived natural products having anticancer activities —	97
3.3.1	Synthesis of lapachol and related derivatives —	97
3.3.2	Synthesis of lapachones and related derivatives —	98
3.3.3	Synthesis of avicequinone B and related derivatives —	101
3.3.4	Synthesis of triphenylphosphonium-conjugated atovaquone derivatives —	102
3.3.5	Synthesis of dunnione and related derivatives —	103
3.4	Conclusions —	104
	References —	104

Aparna Das and Bimal Krishna Banik

4	Advances in heterocycles as DNA intercalating cancer drugs —	111
4.1	Introduction —	111
4.2	Proflavine —	118
4.3	Ethidium bromide —	122
4.4	Doxorubicin —	123
4.5	Dactinomycin —	131
4.6	Bleomycin —	133
4.7	Epirubicin —	136
4.8	Mitoxantrone —	139
4.9	Ellipticine —	140
4.10	Elinafide —	142
4.11	Echinomycin —	145
4.11.1	DNA-binding metallo-intercalators —	147
4.12	Conclusions —	151
	References —	152

Simranpreet K. Wahan and Pooja A. Chawla

5	Recent advances of heterocycle based anticancer hybrids — 161
5.1	Introduction — 161
5.2	Anticancer activity discovered in recently created hybrids — 163
5.2.1	Few oxadiazole ring containing drugs — 163
5.2.2	Recently developed anticancer agents based on thiazole scaffold — 166
5.2.3	Recently developed pyrrole based anticancer agents — 170
5.2.4	Newly fabricated triazole ring containing anticancer derivatives — 174
5.3	Conclusions — 178
	Abbreviations — 179
	References — 179

Dorina Amariuca-Mantu, Vasilichia Antoci, Monica Cornelia Sardaru,
Cristina Maria Al Matarneh, Ionel Mangalagiu and Ramona Danac

6	Fused pyrrolo-pyridines and pyrrolo-(iso)quinoline as anticancer agents — 185
6.1	Introduction — 185
6.2	Fused pyrrolo-pyridines — 186
6.2.1	Indolizines — 186
6.2.2	1 <i>H</i> -pyrrolo[2,3- <i>b</i>]pyridines- <i>b</i> (7-azaindoles) — 192
6.2.3	1 <i>H</i> -pyrrolo[2,3- <i>c</i>]pyridines (6-azaindoles) — 209
6.2.4	1 <i>H</i> -pyrrolo[3,2- <i>b</i>]pyridines (4-azaindoles) — 213
6.2.5	1 <i>H</i> -pyrrolo[3,2- <i>c</i>]pyridines (5-azaindoles) — 216
6.2.6	2 <i>H</i> -pyrrolo[3,4- <i>c</i>]pyridines — 221
6.3	Fused pyrrolo-(iso)quinolines — 223
6.3.1	Pyrrolo[1,2- <i>a</i>]quinoline — 224
6.3.2	Pyrrolo[2,3- <i>b</i>]quinoline — 226
6.3.3	Pyrrolo[2,3- <i>f</i>]quinoline — 227
6.3.4	Pyrrolo[3,2- <i>f</i>]quinoline — 229
6.3.5	Pyrrolo[3,2,1- <i>ij</i>]quinoline — 233
6.3.6	Pyrrolo[1,2- <i>b</i>]isoquinoline — 235
6.3.7	Pyrrolo[2,1- <i>a</i>]isoquinoline — 236
6.4	Conclusions — 239
	References — 240

Basavarajaiah Sulipuldevara Matada, Nagesh Gunavanthrao Yernale
and Jeelan N. Basha

7	Updates on the versatile quinoline heterocycles as anticancer agents — 249
7.1	Overview of cancer and anticancer agents — 249
7.1.1	Definition — 249
7.1.2	Causes of cancer — 249

7.1.3	Cancer symptoms — 250
7.1.4	Types of cancer — 250
7.1.5	Treatment for cancer — 251
7.1.6	Anticancer drugs: — 252
7.2	Introduction to quinolines — 253
7.3	Synthesis of quinolines by classical methods — 254
7.4	Quinoline-based anticancer drugs — 255
7.5	Anticancer activity of quinolines analogs — 257
7.6	Conclusions — 261
	References — 262

Naresh Kumar and Nidhi Goel

8	Recent development of imidazole derivatives as potential anticancer agents — 267
8.1	Introduction — 267
8.2	Structure and chemistry — 269
8.3	General methods of preparation — 270
8.4	Pharmacological activity — 273
8.5	Anticancer activity — 275
8.5.1	Imidazoles as topoisomerases inhibitors — 276
8.5.2	Imidazoles as inhibitors of rapid accelerated fibrosarcoma (RAF) kinases — 278
8.5.3	Anticancer effects of imidazoles as microtubule destabilizing agents — 280
8.5.4	Farnesyltransferase inhibition potential of imidazoles — 283
8.5.5	Imidazole based inhibitors of Transforming growth factor (TGF)- β — 284
8.5.6	Imidazole based molecules as DNA intercalators — 286
8.5.7	Imidazoles inhibiting the STAT-3 — 287
8.5.8	Imidazoles as heat shock protein inhibitors — 288
8.5.9	Natural product based anticancer agents containing imidazole moiety — 288
8.5.10	Imidazole based supramolecules as potential anticancer agents — 289
8.5.11	Imidazoles based CYP26A1 inhibitors — 291
8.6	Future scope of imidazoles based anticancer leads — 292
8.7	Conclusions — 292
	References — 293

Sasadhar Majhi

9	Recent developments in the synthesis and anti-cancer activity of acridine and xanthine-based molecules — 307
9.1	Introduction — 307

9.2	Synthetic analogues of acridine and xanthine —	309
9.2.1	Synthetic analogues of acridine —	309
9.2.2	Synthetic analogues of xanthine —	321
9.3	Modernization at acridine and xanthine-based molecules with anti-cancer activity —	332
9.3.1	Anticancer activity of acridine-based molecules —	332
9.3.2	Anticancer activity of xanthine-based molecules —	334
9.4	Conclusions —	337
	References —	337

Rajiv Karmakar and Chhanda Mukhopadhyay

10	Synthesis of new horizons in benzothiazole scaffold and used in anticancer drug development —	343
10.1	Introduction —	343
10.1.1	Anticancer agents —	344
10.2	Drugs development —	354
10.2.1	Analysis of structure-activity relationship (SAR) regarding anti-cancer activity —	354
10.2.2	Anticancer drug development processes —	356
10.2.3	Synthesis of 2, 3-disubstituted imidazo-benzothiazoles compounds —	363
10.2.4	Synthesis of pyrazolo-benzothiazole hybrids —	371
10.3	Concluding remarks —	380
	References —	381

Jagadees Kumar Gangasani, Siwaswarup Yarasi, Vegi Ganga Modi Naidu and Jayathirtha Rao Vaidya

11	Triazine based chemical entities for anticancer activity —	387
11.1	Introduction —	387
11.1.1	1,2,3-triazines synthesis and anticancer activity —	388
11.1.2	1,2,4-triazines synthesis and anticancer activity —	394
11.1.3	1,3,5-triazines synthesis and anticancer activity —	398
11.2	Conclusions —	414
	References —	414

Yuri de Freitas Rego, Nathália Evelyn Moraes Costa, Rodrigo Martins de Lacerda, Angélica Faleiros da Silva Maia, Cleiton Moreira da Silva and Ângelo de Fátima

12	Anticancer properties of arylchromenes and arylchromans: an overview —	419
12.1	Introduction —	419
12.2	2-Arylchromene and 2-arylchroman derivatives —	421

- 12.3 3-Arylchromene and 3-arylchroman derivatives — 429
- 12.4 4-Arylchromene derivatives — 436
- 12.5 Conclusions — 447
- References — 447

Shashi Kiran Misra, Devender Pathak and Kamla Pathak

- 13 Anticancer potential of indole derivatives: an update — 453**
 - 13.1 Introduction — 453
 - 13.2 Protein kinase inhibitors and cyclin-dependent kinase inhibitors — 457
 - 13.2.1 Cruciferous vegetables — 457
 - 13.2.2 Synthetic indole derivatives: Alectinib, Osimertinib, Tivantinib, Anlotinib, Nintedanib, and Sunitinib — 459
 - 13.2.3 Meridianins — 460
 - 13.2.4 Enzastaurin — 461
 - 13.3 Tubulin inhibitors — 462
 - 13.3.1 Vinca alkaloids — 462
 - 13.3.2 Indole chalcone derivatives — 465
 - 13.3.3 Bisindolyl hydrazide-hydrazone derivatives — 467
 - 13.3.4 Arylthioindoles and indole-3-glyoxylamides — 468
 - 13.4 Histone deacetylase inhibitors (HDAC inhibitors) — 469
 - 13.4.1 Dacinostat — 469
 - 13.4.2 SAHA — 469
 - 13.4.3 SL142 and SL325 — 469
 - 13.4.4 1-Arylsulfonyl-5-(*N*-hydroxyacrylamide) indoles — 470
 - 13.5 DNA topoisomerase inhibitors — 470
 - 13.5.1 Bis(hydroxymethyl)indolizino-indoles — 471
 - 13.5.2 Makaluvamine — 471
 - 13.5.3 Bisindolylalkanes (Hybrid BO-1978) — 472
 - 13.5.4 Indole-based Ursolic acid bearing *N*-aminoalkyl side chains — 473
 - 13.6 Conclusion — 473
 - References — 473

Sunil Kumar, Madhuri T. Patil and Deepak B. Salunke

- 14 Indole based prostate cancer agents — 479**
 - 14.1 Introduction — 479
 - 14.2 Indole linked heterocyclic prostate cancer agents — 481
 - 14.3 Fused indole derivatives as prostate cancer agents — 493
 - References — 498

Index — 503